Literature DB >> 21081184

Evaluation of viscoelastic poly(ethylene glycol) sols as vitreous substitutes in an experimental vitrectomy model in rabbits.

Christopher D Pritchard1, Sven Crafoord, Sten Andréasson, Karin M Arnér, Timothy M O'Shea, Robert Langer, Fredrik K Ghosh.   

Abstract

The aim of this study was to employ an experimental protocol for in vivo evaluation of sols of 5 wt.% poly(ethylene glycol) (PEG) in phosphate-buffered saline as artificial vitreous substitutes. A 20 gauge pars plana vitrectomy and posterior vitreous detachment were performed in the right eye of eight pigmented rabbits. Approximately 1 ml of the viscoelastic PEG sols was then injected into the vitreous space of six eyes. PEG with an average molecular weight of 300,000 and 400,000 g mol(-1) was used in two and four eyes, respectively. Two eyes received balanced salt solution and served as controls. Full-field electroretinography was carried out and intra-ocular pressure (IOP, palpation) measured pre- and post-operatively at regular intervals up to 41 days. The rabbits were killed and the eyes examined by retinal photography, gross macroscopic examination and histology. The viscoelastic sols were successfully injected and remained translucent throughout the post-operative period, with some inferior formation of precipitates. None of the eyes displayed IOP elevation post-operatively, but in three of the PEG sol injected eyes transient hypotony was noted. One eye sustained retinal detachment during surgery and another two in the post-operative period. ERG recordings confirmed preservation of retinal function in three out of four eyes injected with 400,000 g mol(-1) PEG. Histological examination revealed up-regulation of glial acidic fibrillary protein in Müller cells in PEG sol injected eyes, but normal overall morphology in eyes with attached retinas. The viscosity of the sol was not retained throughout the post-operative period, indicating the demand for polymer cross-linking to increase residence time. The results provide promising preliminary results on the use of PEG hydrogels as a vitreous substitute.
Copyright © 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21081184      PMCID: PMC4059419          DOI: 10.1016/j.actbio.2010.11.013

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  25 in total

1.  Use of perfluorohexyloctane as a long-term internal tamponade agent in complicated retinal detachment surgery.

Authors:  Bernd Kirchhof; David Wong; Jan Van Meurs; Ralf D Hilgers; Marc Macek; Noemi Lois; Norbert F Schrage
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

2.  Replacement of the liquid vitreus with sodium hyaluronate in monkeys. I. Short-term evaluation.

Authors:  J L Denlinger; E A Balazs
Journal:  Exp Eye Res       Date:  1980-07       Impact factor: 3.467

3.  Replacement of the liquid vitreus with sodium hyaluronate in monkeys. II. Long-term evaluation.

Authors:  J L Denlinger; A A El-Mofty; E A Balazs
Journal:  Exp Eye Res       Date:  1980-07       Impact factor: 3.467

4.  Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation.

Authors:  Nancy M Holekamp; Ying-Bo Shui; David C Beebe
Journal:  Am J Ophthalmol       Date:  2005-02       Impact factor: 5.258

5.  Experimental vitreous tamponade using polyalkylimide hydrogel.

Authors:  Sven Crafoord; Sten Andreasson; Fredrik Ghosh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-31       Impact factor: 3.117

6.  Biodegradation in vitro and retention in the rabbit eye of crosslinked poly(1-vinyl-2-pyrrolidinone) hydrogel as a vitreous substitute.

Authors:  Y Hong; T V Chirila; S Vijayasekaran; W Shen; X Lou; P D Dalton
Journal:  J Biomed Mater Res       Date:  1998-03-15

7.  The polyalkylimide gel: experience with Bio-Alcamid.

Authors:  B Lafarge Claoue; P Rabineau
Journal:  Semin Cutan Med Surg       Date:  2004-12

8.  Healon in retinal detachment with proliferative vitreoretinopathy.

Authors:  E Gerke; G Meyer-Schwickerath; A Wessing
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1984       Impact factor: 3.117

9.  Comparison of vitreous replacement with Healon and with HPMC in rabbits' eyes.

Authors:  R Koster; J S Stilma
Journal:  Doc Ophthalmol       Date:  1986-01-15       Impact factor: 2.379

10.  Healon as intravitreal substitute in retinal detachment surgery in 40 patients.

Authors:  R Koster; J S Stilma
Journal:  Doc Ophthalmol       Date:  1986-12-30       Impact factor: 2.379

View more
  5 in total

1.  Vitreous substitutes: challenges and directions.

Authors:  Qian-Ying Gao; Yue Fu; Yan-Nian Hui
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

2.  Preliminary study of the safety and efficacy of medium-chain triglycerides for use as an intraocular tamponading agent in minipigs.

Authors:  Vincent J Soler; Camille Laurent; Frédéric Sakr; Alain Regnier; Cyrielle Tricoire; Olivier Cases; Renata Kozyraki; Jean-Yves Douet; Véronique Pagot-Mathis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-05-25       Impact factor: 3.117

3.  A cross-linked hyaluronic acid hydrogel (Healaflow(®)) as a novel vitreous substitute.

Authors:  Henrik Barth; Sven Crafoord; Sten Andréasson; Fredrik Ghosh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-01-08       Impact factor: 3.117

4.  A new model for in vitro testing of vitreous substitute candidates.

Authors:  Henrik Barth; Sven Crafoord; Timothy M O'Shea; Christopher D Pritchard; Robert Langer; Fredrik Ghosh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-25       Impact factor: 3.117

5.  Scleral Buckling with Viscoelastics or Gas Injection for Bulging Retinal Detachments: A Retrospective Cohort Study.

Authors:  Quan-Yong Yi; Wen-Die Li; Qian Gui; Sang-Sang Wang; Li-Shuang Chen; Jing-Hai Mao; Yan Gong; Xia-Jun Wang
Journal:  J Ophthalmol       Date:  2021-04-08       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.